Fate Therapeutics Beats Q1 EPS, Misses Revenue Estimate, Extends Runway to 2028
FATE•Fate Therapeutics posted Q1 EPS of -$0.26, beating the -$0.30 estimate, while revenue fell to $1.3 million versus $1.49 million expected. The company will start its FT819 Phase 2 trial in H2 2026 and has extended its cash runway into 2028 after cutting operating expenses 20%.
1. Q1 Financial Results
Fate Therapeutics reported first-quarter EPS of -$0.26, outperforming the consensus estimate of -$0.30 and improving from -$0.32 a year ago. Revenue declined to $1.3 million, missing the $1.49 million forecast and down from $1.63 million in the prior-year period, marking a 20% year-over-year drop.
2. FT819 Phase 2 Trial Progress
The company confirmed that its FT819 Phase 2 clinical trial remains on schedule to begin in the second half of 2026, advancing its allogeneic CAR-T therapy program for systemic lupus erythematosus. Maintaining this timeline is pivotal for upcoming data catalysts and potential partnerships or licensing deals.
3. Cost Reduction and Cash Runway
Fate Therapeutics reduced operating expenses by 20% in Q1, a restructuring move that extends its cash runway into 2028. This cost discipline is designed to preserve capital as the company advances multiple clinical programs without immediate revenue sources.
4. Balance Sheet and Liquidity
Despite unprofitability reflected in a negative P/E ratio of -1.82, the company holds a strong current ratio of 5.85, indicating robust short-term liquidity. This financial position supports continued R&D investment and operational flexibility through key development milestones.
